NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

ADMA Biologics, Inc. (ADMA) Stock Analysis

ADMA Biologics, Inc. (ADMA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ADMA

$11.01

−$0.22 (−1.96%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ADMA with… →

ADMA Key Statistics

As of Oct 21, 2026
Trading
Open
$11.17
Previous Close
$11.23
Day's Range
10.93–11.28
52-Week Range
7.21–20.46
Volume
2.01M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.69
Valuation
Market Cap
$2.47B
P/E Ratio
15.73
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
11.67
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.81
EPS (ttm)Profit attributable to each share over the last twelve months.
0.70
Financials (FY)
Revenue (FY)
$510.17M+19.63%
Net Income (FY)
$146.93M−25.67%
Profit marginThe share of revenue left as profit after all costs and taxes.
32.98%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
223.98M
1-Year Return
−25.18%
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
2.65M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ADMA closed at $11.01, −25.18% over 1 year.

ADMA Biologics, Inc. (ADMA) has a market capitalization of $2.47B.

In fiscal 2025, ADMA reported revenue of $510.17M.

ADMA Stock Return by Calendar Year

ADMA Biologics, Inc. (ADMA) 10-year return: what $10,000 became

1 year
$10,000 $7,482
−25.18%
5 years
$10,000 $90,992
+809.92%
10 years
$10,000 $17,616
+76.16%

If you had invested $10,000 in ADMA Biologics, Inc. (ADMA) 10 years ago, at the close on October 21, 2016, it would have been worth $17,616 at the close on October 21, 2026: +76.16% in total, +5.83% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−39.64%
2025+6.36%
2024+279.42%
2023+16.49%
2022+175.18%
2021−27.69%
2020−51.25%
2019+67.36%
2018−25.55%
2017−37.30%
2016 (partial year)−18.08%

As of October 21, 2026.

ADMA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$510.17M$146.93M28.8%
2024$426.45M$197.67M46.4%
2023$258.22M−$28.24M−10.9%
2022$154.08M−$65.90M−42.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$510.17M$292.77M$191.44M$146.93M28.8%
2024$426.45M$219.55M$138.98M$197.67M46.4%
2023$258.22M$88.94M$21.63M−$28.24M−10.9%
2022$154.08M$35.27M−$39.37M−$65.90M−42.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ADMA Valuation vs Biotechnology Median

Median of 608 stocks
MetricADMABiotechnology medianvs median
P/E15.7316.605% below
P/S ratio4.8113.3064% below
Profit margin32.98%−38.31%71.3 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ADMA Biologics, Inc. (ADMA) carries a market capitalisation of $2.47B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 640 employees.

The most recent close on file for ADMA is $11.01, dated October 21, 2026. That is −$0.22 (−1.96%) against the previous close. Over the past 52 weeks the price has ranged from $7.21 to $20.46. The latest close sits 52.7% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $510.17M. Against the prior fiscal year total of $426.45M, that is a change of +19.63%. The same year closed with net income of $146.93M. That is −25.67% against the prior fiscal year. The reported profit margin is 32.98%. That is 71.3 percentage points above the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to 0.7.

Across the 4 fiscal years on file, revenue moves from $154.08M in 2022 to $510.17M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 15.73 times earnings. That is 5.24% below the Biotechnology median of 16.6. On forward earnings the ratio is 11.67. The price-to-sales ratio is 4.81. On price-to-sales that is 63.8% below the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −25.18%. Across 10 years the annualized return works out at +5.83%. The reported beta is 0.69. Daily returns over the trailing 10 years annualize to a volatility of 68.42%.

Growth & Income

The record shows no dividend for ADMA.

Across the complete calendar years on file, 2024 returned +279.42% and 2020 returned −51.25%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the total return is −39.64% year to date.

Peer Comparison

ADMA Biologics, Inc. (ADMA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
ADMA Biologics, Inc. ADMA $2.47B 15.7
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. ADMA Biologics, Inc. trades at a P/E of 15.7.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About ADMA Biologics, Inc.

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Visit website →